Garry Brown
Radiation Oncology · Bolivar, MONPI 1043366925
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 99 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $591 and has fallen 86.7% since, to $79 in 2025.
Across 99 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$231
- AstraZeneca$160
- Johnson & Johnson$144
- Amgen$128
- Seagen Inc.$92
- Karyopharm Therapeutics Inc.$77
- plus $742 from 26 others
What the payments were for
- Food & beverage$1,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 19 | $231 |
| AstraZeneca | 8 | $160 |
| Johnson & Johnson | 10 | $144 |
| Amgen | 8 | $128 |
| Seagen Inc. | 6 | $92 |
| Karyopharm Therapeutics Inc. | 4 | $77 |
| Sanofi | 4 | $76 |
| Eisai Inc. | 4 | $75 |
| Puma Biotechnology, Inc. | 3 | $53 |
| AbbVie | 3 | $47 |
| Incyte Corporation | 3 | $43 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Merck | 2 | $36 |
| Beigene USA, Inc. | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| GSK | 2 | $30 |
| Dova Pharmaceuticals | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $27 |
| Bristol Myers Squibb | 1 | $24 |
| Tersera Therapeutics LLC | 1 | $23 |
| Acceleron Pharma, Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $16 |
| Pfizer | 1 | $16 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Advanced Accelerator Applications | 1 | $14 |
| EMD Serono, Inc. | 1 | $14 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $13 |
| Agios Pharmaceuticals, Inc. | 1 | $12 |
| Lilly USA, LLC | 1 | $11 |
How this compares
$1,575 in reported general payments places this provider in the 60th percentile of 123 radiation oncology providers in Missouri.
Other radiation oncology in Bolivar
- Clifford RobinsonSaint Louis$817K
- Carlos PerezSpringfield$103K
- Pamela SamsonSaint Louis$95K
- Jeffrey BradleySaint Louis$75K
- Christopher SpencerRolla$70K
- Matthew SprakerSaint Louis$61K
- Lauren HenkeSaint Louis$45K
- Jeff MichalskiSaint Louis$44K
- Gregory BiedermannColumbia$41K
- Sunpreet RakhraKansas City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.